Abstract:RNA repeat expansions fold into stable structures and cause microsatellite diseases such as Huntington's disease (HD), myotonic dystrophy type 1 (DM1), and spinocerebellar ataxias (SCAs). The trinucleotide expansion of r(CAG), or r(CAG)exp, causes both HD and SCA3, and the RNA's toxicity has been traced to its translation into polyglutamine (polyQ; HD) as well as aberrant pre-mRNA alternative splicing (SCA3). Previously, a small molecule, 1, was discovered that binds to r(CAG)exp and rescues aberrant pre-mRNA splicing in patient-derived fibroblasts by freeing proteins bound to the repeats. Here, we report the structures of single r(CAG) repeat motif (5'CAG/3'GAC where the underlined adenosines form a 1x1 nucleotide internal loop) in complex with 1 and two other small molecules via nuclear magnetic resonance (NMR) spectroscopy combined with simulated annealing. Compound 2 was designed based on the structure of 1 bound to the RNA while 3 was selected as a diverse chemical scaffold. The three complexes, although adopting different 3D binding pockets upon ligand binding, are stabilized by a combination of stacking interactions with the internal loop's closing GC base pairs, hydrogen bonds, and van der Waals interactions. Molecular dynamics (MD) simulations performed with NMR-derived restraints show that the RNA is stretched and bent upon ligand binding with significant changes in propeller-twist and opening. Compound 3 has a distinct mode of binding by insertion into the helix, displacing one of loop nucleotides into the major groove and affording a rod-like shape binding pocket. In contrast, 1 and 2 are groove binders. A series of single molecule studies provide a mechanistic explanation for how bioactive compounds might rescue disease-associated cellular phenotypes.

Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Biological effects of low level exposures to ionizing radiation: Theory and practice

Software quality assurance: Testing and validation

Reversible cardiac disease features in an inducible CUG repeat RNA–expressing mouse model of myotonic dystrophy

Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers Targeting a Toxic r(CUG) Repeat Expansion

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing

Chemical characterization of substance P-like immunoreactivity in primary afferent neurones

Robust CRISPR/dCas13 RNA blockers specifically perturb miRNA-target interactions and rescue type 1 myotonic dystrophy pathology

Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

[Direct determination of water-soluble antimony(III) and antimony(V) in soil by hydride generation atomic fluorescence spectrometry].

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1

NMR structures and magnetic force spectroscopy studies of small molecules binding to models of an RNA CAG repeat expansion

Targeting mutant fibroblast growth factor receptors in cancer.

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences

Megabase-Scale Transgene De-Duplication to Generate a Functional Single-Copy Full-Length Humanized DMD Mouse Model

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

Cas9 nickase-mediated contraction of CAG/CTG repeats at multiple disease loci

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

A New Compact Microstrip Integrated E-Array Patch Antenna with High Gain and High Aperture Efficiency